Dr Maarten Kraan joined AstraZeneca in 2010 as Senior Vice President and Head of the Respiratory, Inflammation and Autoimmunity iMed based in Mölndal, Sweden.

He initially trained as a physiotherapist and after two years working in the field started medical school at Leiden University in 1985, where he also trained as an internist/rheumatologist. Here he completed his PhD programme on synovial tissue analysis and was lead investigator in numerous clinical trials in rheumatoid and psoriatic arthritis. In 1998 he moved to the University of Amsterdam as an Associate Professor, focusing on translational medicine.

In 2003, he joined Schering Plough in Kenilworth, NJ, to build a translational medicine unit in the area of inflammation. He was also heavily involved in the development of both small molecule and large molecule programs in these disease areas. In 2008, Maarten joined Bristol-Myers Squibb in Princeton, NJ, to head the Immunoscience group, supporting the commercialization of products such as abatacept and belatacept. In 2009, he became the global head of the inflammation translational medicine group at Roche in Nutley, NJ, which focuses on COPD, asthma and autoimmune diseases with an opportunistic approach to other inflammatory diseases.